Ph.D., University of Washington, 1989.
M.Math., University of Waterloo, 1985.
B.S., Simon Fraser University, 1984.
My research interests include the design and analysis of clinical trials, methods for exploratory analysis of survival data and adaptive non-parametric regression.
Most of my collaborative research focuses on the design, analysis and conduct of therapeutic clinical trials. I lead the statistical activities related to Phase II and Phase III clinical trials in lymphoma for the Southwest Oncology Group (SWOG). Recently I have been investigating design and analysis methods for targeting patient subgroups appropriate for both Phase II and Phase III clinical trials.
I am interested in the study of adaptive regression methods and their application to data arising from clinical trials. I have developed extensions or alternatives to tree-based methods to yield simple prognostic decision rules in collaboration with Dr. John Crowley (Cancer Research And Biostatistics, CRAB). One example of such methodology is a strategy for constructing prognostic groups based on recursive refinement or peeling algorithms which allow for calibration of the risk group in terms of outcome or fraction of patients in the group.
In addition, I have recently developed an algorithm called Extreme Regression for constructing either high- or low-risk outcome groups in collaboration with Dr. Charles Kooperberg and James Moon (FHCRC). The model leads to a simple inverse regression function which is represented as a Boolean decision rule similar to tree models. However, unlike trees, the new method can control the fraction of subjects identified by the rule.
Some of my other work has included methods for analyzing gene-expression and SNP data. A successful project was Logic Regression, a method which constructs predictors based on Boolean combinations of binary feature variables (led by Charles Kooperberg and originally part of Ingo Ruczinski's dissertation).
I am also currently working on methods that allow specification of genetic structure into the high dimensional regression problem.
1996-2001, Associate Member, Fred Hutchinson Cancer Research Center
1995-1996, Assistant Member, Fred Hutchinson Cancer Research Center
1990-1995, Assistant Professor, University of Toronto, Preventive Medicine and Biostatistics
Comparison of Survival Outcomes Among Cancer Patients Treated In and Out of Clinical Trials.. Journal of the National Cancer Institute.. 2014.
Historical Controls for Metastatic Pancreatic Cancer: Benchmarks for Planning and Analyzing Single Arm Phase II Trials.. Clinical cancer research : an official journal of the American Association for Cancer Research.. 2014.
Clinical Significance of MYC Expression and/or "High-grade" Morphology in Non-Burkitt, Diffuse Aggressive B-cell Lymphomas: A SWOG S9704 Correlative Study.. The American journal of surgical pathology. 38(4):494-501.. 2014.
Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma.. The New England journal of medicine. 369(18):1681-90.. 2013.
MyoD Is a Tumor Suppressor Gene in Medulloblastoma.. Cancer research.. 2013.
Modeling the relationship between progression-free survival and overall survival: the phase II/III trial.. Clinical cancer research : an official journal of the American Association for Cancer Research. 19(10):2646-56.. 2013.
Early phase trial design for assessing several dose levels for toxicity and efficacy for targeted agents.. Clinical trials (London, England).. 2013.
Phase III Randomized Intergroup Trial of CHOP Plus Rituximab Compared With CHOP Chemotherapy Plus 131Iodine-Tositumomab for Previously Untreated Follicular Non-Hodgkin Lymphoma: SWOG S0016.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(3):314-20.. 2013.
A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP-Rituximab versus CHOP + 131Iodine--Tositumomab.. Clinical cancer research : an official journal of the American Association for Cancer Research. 19(23):6624-32.. 2013.
Second Issue for Computational Statistics for Clinical Research. Computational Statistics & Data Analysis. 56(5):995-997.. 2012.
Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model.. Proceedings of the National Academy of Sciences of the United States of America. 109(20):7859-64.. 2012.
Development and use of integral assays in clinical trials.. Clinical cancer research : an official journal of the American Association for Cancer Research. 18(6):1540-6.. 2012.
Two-stage testing procedures with independent filtering for genome-wide gene-environment interaction.. Biometrika. 99(4):929-944.. 2012.
Choosing Phase II Endpoints and Designs: Evaluating the Possibilities.. Clinical cancer research : an official journal of the American Association for Cancer Research. 18(8):2130-2.. 2012.
More randomization in phase II trials: necessary but not sufficient.. Journal of the National Cancer Institute. 103(14):1075-7.. 2011.
Seamless phase I-II trial design for assessing toxicity and efficacy for targeted agents.. Clinical cancer research : an official journal of the American Association for Cancer Research. 17(4):640-6.. 2011.
Risk prediction using genome-wide association studies.. Genetic epidemiology. 34(7):643-52.. 2010.
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.. Clinical cancer research : an official journal of the American Association for Cancer Research. 16(6):1764-9.. 2010.
Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study.. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 21(6):1196-202.. 2010.